Recently, DNA methyltransferase 3A (DNMT3A) mutations have been identified in acute myeloid leukemia (AML), the highest frequency being found within cytogenetically normal (CN) AML. In this study, diagnostic samples from 123 adults younger than 60 years with primary CN-AML homogeneously treated in the Acute Leukemia French Association-9801 and -9802 trials were screened for mutations in DNMT3A-conserved domains by direct sequencing. Patients were also assessed for the presence of FLT3 (fms-like tyrosine kinase receptor-3), NPM1 (nucleophosmin), CEBPA, WT1 (Wilms tumor 1), IDH1 (isocitrate dehydrogenase 1) and IDH2 mutations. Thirty-eight mutations were detected in 36 patients (29%): 36 nucleotide substitutions, mostly affecting amino-acid residue R882 and two frameshift deletions. DNMT3A mutations were significantly associated with the French --American --British subtypes M4/M5 and the presence of NPM1 mutations. In the whole cohort, DNMT3A mutated patients had a shorter event-free survival (5-year EFS: 13% vs 32%, P ¼ 0.02) and overall survival (5-year OS: 23% vs 45%, P ¼ 0.02) compared with DNMT3A wild-type patients. In multivariate analysis including age, white blood cell count, NPM1/FLT3-internal tandem duplication/CEBPA risk group and DNMT3A mutational status, the presence of a DNMT3A mutation remained an independent adverse prognostic factor for EFS and OS, suggesting that testing for DNMT3A mutations could help further improve risk stratification in CN-AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a biologically and clinically heterogeneous disease. Cytogenetically normal (CN) AML represents the largest subgroup of adult patients with AML. During the last 15 years, major advances have been made in the understanding of CN-AML pathogenesis by the discovery of many genetic abnormalities affecting cell proliferation, differentiation, apoptosis or cell cycle regulation. These abnormalities include many gene mutations (NPM1 (nucleophosmin), FLT3 (fms-like tyrosine kinase receptor-3), CEBPA, MLL, N-RAS, RUNX1 (Runtrelated transcription factor 1), WT1 (Wilms tumor 1) and so on), 1 deregulation of gene expression (EVI1 (Ecotropic Viral Integration Site 1), BAALC (brain and acute leukemia, cytoplasmic), MN1 (meningioma 1), ERG (Ets-related gene), WT1 and so on), 2 --8 as well as acquired copy number variations and regions with loss of heterozygosity. 9, 10 Prognostic significance within CN-AML has been well established for FLT3 internal tandem duplication (FLT3-ITD), NPM1 and CEBPA mutations. 11, 12 NPM1 mutations confer a relatively favorable clinical outcome in CN-AML in the absence of a concomitant adverse FLT3-ITD.
13 --15 CN-AML with CEBPA mutations define another subgroup of patients also associated with a favorable prognosis. 11, 12, 16 More recently, several studies have demonstrated that only AML with biallelic CEBPA mutations (most of them being double CEBPA mutations) should be regarded as favorable. 17 --21 Mutations in NPM1, CEBPA and FLT3-ITD allowed a refined prognostic classification of CN-AML and improved risk stratification in this subset of AML patients. 11, 12 However, the molecular heterogeneity of CN-AML remains only partially resolved.
Whole-genome sequencing has opened a new era toward knowledge of the molecular basis of AML. The development of massively parallel sequencing technologies led to the identification of mutations in IDH1, 22 and subsequently in related gene IDH2, 23 as recurrent genetic events in AML. Recently, three studies using a similar approach revealed the presence of somatic mutations in DNA methyltransferase 3A (DNMT3A) gene in approximately 20% of AML patients, with the highest frequency being found in CN-AML. 24 --26 DNMTs catalyze the conversion of cytosine to 5-methylcytosine. The major DNMTs with methyltransferase activity in humans are DNMT1, DNMT3A and DMNT3B. DNMT1 is essential to maintain existing methylation after cell division, while DNMT3A and DMNT3B are responsible for de novo DNA methylation and function independently of replication. DNA cytosine methylation is a crucial epigenetic modification involved in the control of various cellular processes, including gene expression regulation and chromatin structural remodeling. Cancer genomes are characterized by global DNA hypomethylation with concomitant hypermethylation of CpG islands in the promoters of tumor-suppressor genes. Disruption of normal DNA methylation distribution is a hallmark of cancer and can have critical roles in initiation, progression and maintenance of the malignant phenotype. 27, 28 DNMT3A mutations have been suggested to predict poor clinical outcome in AML, 24,25,29 --31 but only few data are available on their prognostic significance within CN-AML. The aim of this study was to determine the frequency, main associated features and prognostic impact of DNMT3A mutations in a cohort of young adult patients with CN-AML homogeneously treated in two concomitant protocols of the Acute Leukemia French Association (ALFA).
PATIENTS AND METHODS

Patients and treatment
This retrospective study was performed in 123 young adult patients (16 --60 years) with previously untreated de novo CN-AML and enrolled on the prospective French ALFA-9802 and ALFA-9801 trials. These clinical studies were approved by the ethic committees of Lyon B-Hotel Dieu Hospital (ALFA-9802: no. 99017B) and Saint-Louis Hospital (ALFA-9801: no. 9959). ALFA-9802 and ALFA-9801 trials have been registered with http://www.clinicaltrials.gov under identifiers NCT00880243 and NCT00931138, respectively. Treatment schemes have been previously reported for both trials. 32, 33 Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. The median followup for patients who remained alive was 3.9 years.
Cytogenetic analysis
Cytogenetic G-banding analysis was performed according to standard methods. The definition of a cytogenetic clone and descriptions of karyotypes followed the International System for Human Cytogenetic Nomenclature. 34 To establish CN-AML, at least 20 metaphase cells from diagnostic bone marrow (BM) had to be evaluated and the karyotype had to be found normal in each patient.
Analysis of DNMT3A mutations
Genomic DNA was extracted from diagnostic BM or peripheral blood mononuclear cells using standard procedures. The blast percentage following enrichment by Ficoll density gradient centrifugation (MSL, Eurobio, Courtaboeuf, France) was above 60% in all samples. The screening of DNMT3A mutations was performed by PCR and direct Sanger sequencing. We focused our screening on the three conserved domains of DNMT3A: the PWWP domain, characterized by the presence of a highly conserved proline-tryptophane-tryptophane-proline motif, the ADD-type zinc finger (ZNF) domain and the C5-methyltransferase domain. To this purpose, exons 8 --9 and 11 --23 of DNMT3A were amplified from genomic DNA by PCR using the FastStart Taq DNA Polymerase Kit (Roche, Basel, Switzerland) and the intronic (M13-tagged) primers shown in Table 1 . Primers were designed to cover coding sequences and splice sites flanking each analyzed exon. The total reaction volume of 50 
Analysis of other gene mutations
FLT3-ITDs were screened by PCR and fragment analysis using previously described primers 11F (fluorescently labeled) and 12R. 35 PCR products were subjected to capillary electrophoresis on denaturing polyacrylamide gel and analyzed by the CEQ 8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA, USA). Data were processed using Genetic Analysis System Software (Beckman Coulter 41 were assessed centrally as previously described.
Definition of clinical end points
Complete remission (CR) required BM cellularity of at least 20% with maturation in all cell lineages, o5% BM blast cells, no Auer rods, recovery of neutrophils X1.5 G/l and platelet count 4100 000/ml in peripheral blood, as well as no evidence for circulating blasts and/or extramedullary leukemia, all of which had persisted for at least 1 month. Relapse was defined as reoccurrence of more than 5% of leukemic blasts in BM, reappearance of circulating blasts or the development of extramedullary leukemia. 42 Overall survival (OS) was calculated from the date of diagnosis to the date of death, and event-free survival (EFS) from the date of diagnosis to the date of CR achievement failure, first relapse or death, censoring patients alive in CR at last follow-up.
Statistical analysis
The predicted severity of DNMT3A mutations with translational consequences was evaluated using sorting intolerant from tolerant Table 1 . Primer sequences used for DNMT3A mutation screening
Amplicon
Forward primer Reverse primer
DNMT3A mutations in acute myeloid leukemia A Renneville et al algorithm. 43 Patient characteristics and CR rate comparisons were performed using the Fisher exact test for binary variables and the Mann --Whitney test for continuous variables. EFS and OS were estimated by the Kaplan --Meier method and compared using the log-rank test. The effect of continuous variables on EFS and OS was assessed using a Cox proportional hazard regression. Multivariate Cox models were used to evaluate the impact of DNMT3A mutations on EFS and OS when controlling for other well-established prognostic factors. Variables other than DNMT3A mutational status that were considered for model inclusion were age, white blood cell (WBC) count at presentation and NPM1/FLT3-ITD/CEBPA risk group (NPM1 mutated/FLT3-ITD negative or double CEBPA mutated as low risk, and other genotypes as high risk). A P-value p0.05 was considered statistically significant.
RESULTS
Frequency and types of DNMT3A mutations Overall, 38 DNMT3A non-synonymous sequence variants were identified in 36 of the 123 (29%) patients. These alterations consisted of 36 nucleotide substitutions and two frameshift deletions. Out of 36 nucleotide substitutions, 30 (83%) affected the amino-acid residue R882 (R882H, n ¼ 21; R882C, n ¼ 7; R882P, n ¼ 2), 5 represented other missense alterations and 1 was a nonsense mutation ( Figure 1 ). Six novel sequence changes in DNMT3A were found in this study. The somatic status of the identified DNMT3A alterations could not be proven owing to the lack of matched DNA from unaffected tissue. As the presence of mutations resulting in a stop codon in germline DNA is unlikely, tumor-specific origin remains uncertain for four missense variations that have so far not been further characterized. Nevertheless, none of these four variants have previously been reported as single-nucleotide polymorphism. Additionally, they were located in two important functional domains of DNMT3A, the PWWP motif or the methyltransferase domain, and were predicted to affect protein function according to sorting intolerant from tolerant algorithm (Table 2) . Therefore, these four missense variants were pooled together with other DNMT3A mutations and included in further analysis.
All samples showing sequence variants except one retained the wild-type sequence in addition to the mutated sequence, which suggests heterozygosity for the mutant allele in 35/36 patients. Two patients exhibited two heterozygous mutations in different exons, involving in both cases the R882C mutation, which was found concomitantly with a R635W mutation or with a R836W mutation, respectively ( Table 2) . 900  1  700  600  500  400  300  100 200 800 Figure 1 . Location of DNMT3A mutations. The positions and predicted translational consequences of DNMT3A mutations detected in 123 patients with normal karyotype acute myeloid leukemia are shown. Each circle represents a mutation found in one patient. Two patients were found to have two DNMT3A mutations. DNMT3A isoform 1 (912 amino acids) is represented with its three conserved domains figured in gray color. MeTFase, C5-methyltransferase; PWWP, proline-tryptophane-tryptophane-proline; ZNF, zinc finger. Found concomitantly with a R882C mutation. Note: The nucleotide numbering is derived from the Genbank cDNA sequence NM_022552.3, where the A in the ATG initiation codon corresponds to base 1. The numbering of amino-acid residues is according to NCBI reference sequence NP_783328 (isoform 1, 912 amino acids).
PWWP ZNF MeTFase
Patient characteristics in relation to DNMT3A mutation status Pre-treatment patient characteristics of the DNMT3A mutated and wild-type cases are shown in Table 3 . The two groups did not differ in terms of age, gender and WBC count at presentation. DNMT3A mutations were significantly enriched in AML with monocytic lineage involvement as 55% of DNMT3A mutated cases fell into the French --American --British subtypes M4 or M5 vs 21% of DNMT3A wild-type cases (P ¼ 0.0002).
Co-occurrence of DNMT3A mutations with other gene mutations DNMT3A mutations were strongly associated with the presence of NPM1 mutations as 24 of 36 (67%) DNMT3A mutated patients also harbored a NPM1 mutation compared with 28 of 87 (32%) DNMT3A wild-type patients (P ¼ 0.0006). A frequent overlap was also observed between DNMT3A and IDH1R132 mutations, but without reaching statistical significance in our cohort (22% vs 10%, P ¼ 0.09; Table 3 ). In contrast, there was an inverse relationship between the presence of DNMT3A mutations and CEBPA mutations: none of the 36 (0%) DNMT3A mutated patients had a concomitant single or double CEBPA mutation compared with 12 of 86 (14%) DNMT3A wild-type patients (P ¼ 0.017). Similarly, no patient in our cohort presented with both a DNMT3A mutation and a WT1 mutation (P ¼ 0.19). The rates of FLT3-ITD, FLT3-TKD, IDH2R172 and IDH2R140 mutations were found to be similar in DNMT3A mutated and DNMT3A wild-type cases (Table 3 and Figure 2 ).
Prognostic impact of DNMT3A mutations in the whole cohort of CN-AML There was no difference in the distribution of DNMT3A mutated and wild-type patients according to therapy received, including allogeneic hematopoietic stem cell transplantation. Out of 123 patients, 107 (87%) achieved CR after induction chemotherapy. CR rate was not significantly different between DNMT3A mutated and wild-type patients, although CR rate was lower in DNMT3A mutated patients (80% vs 90%, P ¼ 0.24). Compared with DNMT3A wild-type patients, DNMT3A mutated patients had a significantly shorter EFS (5-year EFS: 13% vs 32%, P ¼ 0.02; Figure 3a) and OS (5-year OS: 23% vs 45%, P ¼ 0.02; Figure 3b) (Table 3) . Of note, patients with a R882 DNMT3A mutation (n ¼ 30) and those with another type of DNMT3A mutation (n ¼ 6) had a similar survival (5-year EFS: 16% vs 0%, P ¼ 0.88; 5-year OS: 23% vs 25%, P ¼ 0.72, respectively; Supplementary Figure S1 ).
Among adult CN-AML, the genotypes NPM1 mutated/FLT3-ITD negative or double CEBPA mutated have consistently been associated with a relatively favorable clinical outcome and defined a low-risk subgroup of CN-AML patients.
12 --15,17 --21 In our cohort, we confirmed that these two low-risk genotypes were associated with a better EFS (5-year EFS: 47% vs 18%; P ¼ 0.001) and OS (5-year OS: 57% vs 28%; P ¼ 0.02) compared with other genotypes.
Finally, we performed a multivariate analysis on the end points EFS and OS considering age, WBC count at presentation, NPM1/ FLT3-ITD/CEBPA risk group (low vs high) and DNMT3A mutational status. This analysis revealed that high WBC count at presentation, NPM1/FLT3-ITD/CEBPA high-risk genotypes and DNMT3A mutations were significantly and independently associated with a worse EFS and OS (Table 4) .
Prognostic impact of DNMT3A mutations in molecularly defined subgroups As DNMT3A mutations mainly occurred in AML with NPM1 mutations, we first analyzed the prognostic influence of DNMT3A mutations within NPM1 mutated AML. In our cohort, 52 patients harbored a NPM1 mutation, of whom 24 (46%) had a concomitant DNMT3A mutation. Among patients with CN-AML with NPM1 mutation, CR rate was not significantly different between DNMT3A mutated and wild-type patients (88% vs 93%, P ¼ 0.65), but patients with a DNMT3A mutation had a significantly inferior EFS and OS compared with DNMT3A wild-type patients (5-year EFS: 19% vs 55%, P ¼ 0.01, Figure 4a ; 5-year OS: 24% vs 61%, P ¼ 0.02, Figure 4b) .
We next performed subgroup analysis according to NPM1/FLT3-ITD/CEBPA genotypes. In patients with NPM1/FLT3-ITD/CEBPA low-risk genotypes (defined by the presence of either a NPM1 mutation without FLT3-ITD or a double CEBPA mutation), 18/44 (41%) had a concomitant DNMT3A mutation. CR rate was not Abbreviations: CI, confidence interval; CN-AML, cytogenetically normal acute myeloid leukemia; DNMT3A, DNA methyltransferase 3A; EFS, event-free survival; FLT3, fms-like tyrosine kinase receptor-3; HR, hazard ratio; ITD, internal tandem duplication; NPMI, nucleophosmin; OS, overall survival; WBC, white blood cell.
a Indicates continuous variable.
DNMT3A mutations in acute myeloid leukemia A Renneville et al significantly different between DNMT3A mutated and wild-type patients (94% vs 100%, P ¼ 0.41). In this low-risk subgroup, patients with a DNMT3A mutation had a significantly inferior EFS and OS compared with DNMT3A wild-type patients (5-year EFS: 25% vs 62%, P ¼ 0.007, Figure 4c ; 5-year OS: 29% vs 78%, P ¼ 0.007, Figure 4d ). In patients with NPM1/FLT3-ITD/CEBPA highrisk genotypes (all non-favorable genotypes) (n ¼ 79), the 18 (23%) patients carrying an additional DNMT3A mutation tended to have a lower CR rate compared with DNMT3A wild-type patients (67% vs 85%, P ¼ 0.09). In this high-risk subgroup, DNMT3A mutations conferred a shorter EFS and a trend toward a shorter OS (5-year EFS: 0% vs 19%, P ¼ 0.05, Figure 4e ; 5-year OS: 13% vs 32%, P ¼ .12, Figure 4f ).
DISCUSSION
DNMT3A mutations are the second most common molecular aberration identified in our patient cohort, accounting for nearly one-third of CN-AML, as previously reported in this subset of patients. 24, 29 This high frequency indicates that these mutations probably contribute to AML pathogenesis. We and others 24,25,29 --31,44 found that DNMT3A mutations were strongly associated with FAB M4/M5 subtypes, and often co-occurred with NPM1 or IDH1 mutations in AML patients, suggesting that the oncogenic actions of these mutations are not redundant. DNMT3A mutations were reported to be associated with older age, 24, 25, 30, 31 but this feature was not observed in our cohort of adult CN-AML. Nevertheless, a link between age and the incidence of DNMT3A mutations is likely as these mutations seem to be extremely rare (o1%) in pediatric AML. 45 --47 Among the 11 different DNMT3A mutations identified in our cohort, those affecting R882 residue were the most common, in agreement with previous reports. 24, 25, 29 Interestingly, the somatic R882 mutations in DNMT3A found in AML are analogous to the inherited R823G mutation in DNMT3B, which was discovered in a human syndrome characterized by immunodeficiency, centrosome instability and facial abnormalities (ICF) in association with defects in genomic methylation. 48, 49 In AML, the exact pathogenic mechanism by which DNMT3A mutations act is still enigmatic. Notably, Yan et al. found that DNMT3A mutations enabled 32D cells, an interleukin-3-dependent mouse myeloid cell line, to acquire growth and survival advantage even without growth factor. However, the leukemogenic potential of DNMT3A mutations remains to be proven at an organism level. 25 Most DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. 25, 26 Using methyl-DNA immunoprecipitation chip analysis in AML samples with DNMT3A R882 mutations, Ley et al. 24 identified 182 genomic regions with decreases in DNA methylation, while Yan et al. 25 found almost 4000. Anyway, DNMT3A mutations did not yield a specific pattern of altered DNA methylation, unlike other recurrent genetic abnormalities in AML, such as PML-RARA, CBFB-MYH11 or double CEBPA mutations. 50 Likewise, the influence of DNMT3A mutational status on gene expression profiles is yet unclear, and DNMT3A mutant AML was not found to have a common gene expression signature. 24, 25 Further experiments are needed to identify genes whose expression is modulated by DNMT3A mutations and determine the biological effects of these mutations. We showed that DNMT3A mutations confer a poor prognosis in CN-AML, in line with previous studies in AML. 24,25,29 --31 Given the small number of non-R882 mutants, we could not formally investigate whether or not different types of DNMT3A mutations carry different prognostic significance. In our study, the negative prognostic impact of DNMT3A mutations was observed within different molecular subgroups, including NPM1 mutated patients, NPM1/FLT3-ITD/CEBPA low-risk patients, and to a lesser extent in NPM1/FLT3-ITD/CEBPA high-risk patients. Thol et al. 29 reported that DNMT3A mutations had an unfavorable effect on CR rate, relapsefree survival and OS in NPM1/FLT3-ITD high-risk but not in low-risk CN-AML patients. In contrast, we found that the prognostic effect of DNMT3A mutations on CR rate, relapse-free survival and OS did not reach statistical significance in NPM1/FLT3-ITD high-risk patients, whereas it was significant regarding relapse-free survival and OS within NPM1/FLT3-ITD low-risk patients (data not shown). Factors related to patient and disease characteristics, and differences in treatment modalities may account for these different findings, but the exact reasons for this discordance remain unknown. DNMT3A mutations rarely occur in patients with CEBPA mutations, 30 especially in those with double CEBPA mutations, 51 and the clinical outcome of AML patients who carry both mutations is yet uncertain. 51 In our cohort, the prognostic impact of DNMT3A mutations in patients with CEBPA mutations was not evaluable, as CEBPA and DNMT3A mutations were mutually exclusive.
Although based on a limited number of patients, our data illustrate that DNMT3A mutations can identify new subgroups of CN-AML patients with highly distinct clinical outcome. Particularly, we found that patients with 'NPM1 mutated/FLT3-ITD negative/ DNMT3A wild-type' together with double CEBPA mutants defined a very low-risk subgroup of CN-AML patients, whose long-term survival is close to that of patients with acute promyelocytic leukemia. Conversely, the presence of a non-favorable genotype and an additional DNMT3A mutation characterized a very high-risk subgroup of CN-AML patients who may need more aggressive or investigational therapies. To date, only NPM1, CEBPA and FLT3-ITD mutations have entered clinical practice and affect risk stratification and treatment decision-making in CN-AML. Patients with CN-AML and the favorable genotype NPM1 mutated/FLT3-ITD negative are currently not considered candidates for allogeneic hematopoietic stem cell transplantation in first-line treatment. 11 Similarly, CN-AML patients with double CEBPA mutations may not require allogeneic hematopoietic stem cell transplantation in first CR, but the lack of transplantation benefit has not been substantiated by data for these patients. 7 We showed that DNMT3A mutations provide additional prognostic information to better classify patients with CN-AML and, accordingly, may further improve consolidation treatment stratification in this subset of AML. Whether CN-AML patients with the favorable genotypes NPM1 mutated/FLT3-ITD negative or double CEBPA mutated but a simultaneous DNMT3A mutation may benefit from allogeneic hematopoietic stem cell transplantation in first CR is a question that will need to be addressed in future studies using larger patient cohorts.
A major challenge of whole-cancer-genome analysis is to identify 'driver' mutations. Considering their high occurrence and prognostic significance, it is likely that DNMT3A mutations belong to this category in CN-AML. Of note, DNMT3A mutations have also been reported in other myeloid malignancies, such as myeloproliferative neoplasms 52 and myelodysplastic syndromes, 53 but with a much lower incidence. In myelodysplastic syndromes, DNMT3A mutations also seem to predict poor prognosis with shorter survival and more rapid progression to AML. 53 In conclusion, we showed that DNMT3A mutations represent a powerful and independent adverse prognostic factor that allows the identification of new clinically relevant subsets of adult CN-AML. However, these data require further validation in larger patient cohorts and in the context of other recurrent molecular abnormalities identified in CN-AML. Molecular testing for DNMT3A mutations at AML diagnosis should be incorporated in upcoming clinical trials to firmly evaluate the prognostic significance of these mutations, and their usefulness in the clinical management of adult AML and in the development of targeted therapies.
